drugset / Trial / NCT06777732

The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication

NCT06777732

Phase 0 Not yet recruiting 672 enrolled Nanjing First Hospital, Nanjing Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to compare the efficacy of 14-day eradication of Helicobacter pylori with different doses of Keverprazan combined with Amoxicillin dual therapy and Keverprazan-based bismuth quadruple therapy and compare the adverse reactions, compliance, and factors affecting the efficacy of eradication schemes among different groups.

Timeline

Start
2025-03
Primary completion
2025-09
Completion
2026-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1000 mg
Subject Keverprazan Unknown 10 mg
Subject Keverprazan Unknown 20 mg
Background Furazolidone Small molecule 100 mg
Background colloidal bismuth pectin Unknown 300 mg